AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire
Swanson PA, et al.
October 2021
Authors and Affiliates
Phillip A Swanson 2nd 1, Marcelino Padilla 1, Wesley Hoyland 1, Kelly McGlinchey 2, Paul A Fields 3, Sagida Bibi 4, Saul N Faust 5, Adrian B McDermott 1, Teresa Lambe # 6, Andrew J Pollard # 4, Nicholas M Durham # 7, Elizabeth J Kelly # 8, AstraZeneca/Oxford/VRC Study Group;
1 Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
2 Discovery, Research and Early Development, Oncology R&D, AstraZeneca, Gaithersburg, MD 20878, USA.
3 Adaptive Biotechnologies, Seattle, WA 98102, USA.
4 Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford OX4 6PG, UK.
5 NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton SO16 6YD, UK.
6 The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford OX3 7FZ, UK.
7 Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD 20878, USA.
8 Translational Medicine, Microbial Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA.
# Contributed equally.